Sermorelin vs Hexarelin: what the research actually compares

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal fragment of growth hormone-releasing hormone (GHRH), classified as a GHRH analogue. It is also referred to in the literature as GRF(1-29) or GHRH(1-29). Hexarelin is a synthetic hexapeptide classified as a growth hormone secretagogue (GHS) and is also referred to as examorelin. In the peptide-classification literature, sermorelin is grouped with the GHRH analogues (alongside tesamorelin and the CJC-1295 variants), while hexarelin is grouped with the growth hormone secretagogues (alongside GHRP-2, GHRP-6, and ipamorelin) [4].

The published work on both compounds centres on the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis, with sermorelin acting as a GHRH-receptor agonist and hexarelin acting as a growth hormone secretagogue receptor type 1a (GHS-R1a) agonist [1][4].

Research Studies

Sermorelin and the GH-IGF-1 axis in the peptide-therapy literature

Sermorelin appears in the clinical and regulatory literature as one of the GHRH analogues used to modulate the GH-IGF-1 axis. A review of performance-enhancing peptides marketed as research compounds lists sermorelin among the GHRH analogues most commonly encountered in clinical practice and in online self-administration protocols, alongside tesamorelin and the CJC-1295 variants [4]. That review frames the entire category as unregulated peptides intended to modulate the GH-IGF-1 axis, and it is the principal source in the evidence set that names sermorelin directly [4].

Sermorelin and comparator GHRH analogues in registered trials

The registered-trial evidence in this set does not test sermorelin itself. It tests tesamorelin, a different GHRH analogue, in two populations. In adults with fatty liver disease, a randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin reduces liver fat, quantified by MRI-proton density fat fraction, over 52 weeks, with glucose metrics and IGF-1 monitored for safety [5]. In adults with HIV, a separate trial evaluates whether tesamorelin improves physical function and muscle health when combined with exercise, in a population that shows earlier impairment in physical function and earlier presentation of frailty than the general population [6]. These trials establish what the GHRH-analogue class has been formally tested for; they do not establish anything about sermorelin specifically.

Hexarelin and retinal ganglion cell survival after optic nerve transection

Hexarelin was studied for neuroprotection in the retina after optic nerve transection (ONT) in 8–9-week-old golden hamsters. In a one-dose-per-day design, animals received saline or hexarelin at 25 μg/kg, 50 μg/kg, or 100 μg/kg daily for 5 days following ONT; in a two-dose-per-day design, animals received saline or hexarelin at 100 μg/kg or 150 μg/kg twice daily for 5 days. Retinal ganglion cell survival was quantified by Tuj1 immunostaining [1]. The study describes hexarelin as a GHS-R1a agonist with a potent anti-apoptotic effect and reports a neuroprotective effect on retinal ganglion cell survival in this model [1].

Hexarelin and ischemic acute kidney injury via MDM2/p53

Hexarelin was investigated in ischemia/reperfusion-induced acute kidney injury (AKI) using both in vivo and in vitro experiments. In the in vivo model, rats were pretreated with hexarelin at 100 μg/kg/day for 7 days and sacrificed 24 hours after ischemia/reperfusion injury; kidney function, histology, and apoptosis were then assessed [2]. The stated mechanism is alleviation of apoptosis via the MDM2/p53 pathway [2]. The paper notes that hexarelin shows significant protection against organ injury in models of ischemia/reperfusion-induced injury, while its impact on AKI and its underlying mechanism had been unclear [2].

Hexarelin and MPTP-induced lung injury in mice

A separate study examined protective and therapeutic effects of hexarelin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced lung injury in mice, evaluating oxidative stress, IL-6-mediated inflammation, and caspase-3-dependent apoptosis. Fifty male Balb/C mice were used [9]. This is a distinct injury model from the retinal and renal work and adds a third tissue context in which hexarelin has been tested preclinically.

Hexarelin and GHS-R1a pharmacology

Across the preclinical studies in this set, hexarelin is characterised as a GHS-R1a agonist [1]. The peptide-classification review places hexarelin within the growth hormone secretagogue group, the same group as GHRP-2, GHRP-6, and ipamorelin, and distinguishes that group from the GHRH analogues [4]. This receptor-level distinction is the clearest pharmacological difference the evidence supports between the two compounds: sermorelin is described as a GHRH analogue, hexarelin as a GHS-R1a agonist [1][4].

Hexarelin and musculoskeletal or sports-medicine peptide reviews

Hexarelin is named in reviews of peptide use in sport and bodybuilding, which describe growth hormone secretagogues as agents marketed as more selective and ostensibly safer alternatives to anabolic-androgenic steroids [11]. A separate review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance notes that peptide use in sports medicine is expanding, driven by patient demand for accelerated injury recovery and performance enhancement, while distinguishing peptides that have undergone rigorous approval pathways from those that have not [10]. Neither review reports a controlled trial of hexarelin for a musculoskeletal or performance endpoint.

Hexarelin and long-term growth hormone exposure: a case report

A case report describes a 62-year-old male ex-military recreational bodybuilder, a long-term growth hormone user, who presented with cervicalgia and left shoulder pain. Cervical radiographs and MRI showed multilevel degenerative changes including a prominent anterior osteophyte at C3-C4 with esophageal compression; on directed questioning he reported intermittent dysphagia with larger food boluses, and he reported a cervical injury during jiu-jitsu [3]. The report notes that symptomatic osteophytic dysphagia is underdiagnosed and that the role of systemic anabolic factors in osteophyte growth is poorly characterised [3]. This is a single case and does not establish causation for any specific compound.

Hexarelin and hyper-inflammatory responses in a CD36-modulator study

A study of pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2 in K18-hACE2 mice used a cluster of differentiation 36 receptor modulator, in a context where the hyper-inflammatory response progressing to acute respiratory distress syndrome remained an unmet medical need [8]. This study is included here as part of the broader preclinical literature on peptide and receptor-modulator approaches to inflammatory injury; it does not report a hexarelin or sermorelin arm.

Where the two compounds sit side by side

What is not known

The evidence set contains no head-to-head study of sermorelin and hexarelin. It contains no registered trial of sermorelin; the registered trials present test tesamorelin, a different GHRH analogue, in fatty liver disease and in adults with HIV [5][6]. It contains no registered trial of hexarelin. The hexarelin findings are preclinical and model-specific: retinal ganglion cell survival after optic nerve transection in hamsters [1], ischemia/reperfusion AKI in rats [2], and MPTP-induced lung injury in mice [9]. The case report involving long-term growth hormone use is a single observation and does not attribute an outcome to either compound [3]. The reviews of peptide use in sport and orthopaedics describe the category and its regulatory status but report no controlled efficacy data for either compound [10][11][12].

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection. https://europepmc.org/article/PMC/PMC13004568
• [2] Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. https://europepmc.org/article/PMC/PMC10500723
• [3] Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report. https://europepmc.org/article/PMC/PMC13375183
• [4] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. https://europepmc.org/article/PMC/PMC13322892
• [5] Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease. https://clinicaltrials.gov/study/NCT07481734
• [6] Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV. https://clinicaltrials.gov/study/NCT06554717
• [7] Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation. https://clinicaltrials.gov/study/NCT06701071
• [8] Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator. https://europepmc.org/article/PMC/PMC10879382
• [9] Protective and restorative effects of hexarelin on MPTP-induced lung injury in mice. https://pubmed.ncbi.nlm.nih.gov/42619489/
• [10] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://pubmed.ncbi.nlm.nih.gov/41966639/
• [11] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. https://pubmed.ncbi.nlm.nih.gov/41880199/
• [12] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://europepmc.org/article/PMC/PMC12753158